[Treatment of extrinsic bronchial asthma with transfer factor].
A group of 90 external asthmatics with cellular immunodeficiency or not was studied and treated during 10 months with transfer factor or double blind placebo. Total immunoglobulin serum studies (A, G, M and E), spontaneous rosette and intradermal tests, were made a month before the treatment's beginning and a month after the ending of the treatment. The patients were clinically evaluated every day in accordance to the intensity and the frequency of their crisis and with the immunological point of view of the tests made. There was not significant differences between the study groups treated with the transfer factor or not. Adverse reactions were not noticed.
Valdés Sánchez
A F
AF
Servicio de alergología, Hospital Clínico Quirúrgico Hermanos Ameljeiras, La Habana, Cuba.
Martín Rodríguez
O L
OL
Lastra Alfonso
G
G
D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000628:therapy*; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D016867:Immunocompromised Host; D007073:Immunoglobulin E / Q000097:blood; D007136:Immunoglobulins / Q000032:analysis; D007428:Intradermal Tests; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D012397:Rosette Formation; D016176:T-Lymphocyte Subsets / Q000187:drug effects; D014165:Transfer Factor / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D007136:Immunoglobulins; D014165:Transfer Factor; D007073:Immunoglobulin E